Start Your Free Review
Answer 2-3 quick questions to review your potential case.
Verified against court records, regulatory records, and peer-reviewed research.
Why Military Women Were Disproportionately Affected
Depo-Provera was frequently prescribed to active-duty servicewomen because its 12-week injection schedule was considered more practical for deployment than daily pills. Military medical providers often recommended injectable contraception for women preparing for deployment to combat zones or remote locations where daily medication adherence and supply chains were challenging.
The Deployment Contraception Challenge
A study of deployed U.S. servicewomen found that 65% used contraception during deployment. While long-acting reversible contraception (LARC) methods like IUDs and implants have grown in popularity, many women received Depo-Provera injections — particularly in earlier decades when LARC options were less available in military healthcare settings. Some women received injections for years across multiple deployments.
VA Benefits and Civil Lawsuits
Military veterans diagnosed with meningioma after Depo-Provera use may pursue two separate avenues: a civil lawsuit against Pfizer through MDL 3140 (for monetary damages) and a VA disability claim if the meningioma is connected to military service or treatment. These are not mutually exclusive — you can pursue both simultaneously.
How to File as a Veteran
Gather your military medical records showing Depo-Provera prescriptions (available through the National Personnel Records Center or your VA medical file). Document the timeline of injections during military service. Consult an attorney experienced in both pharmaceutical mass tort and military/veterans' law.
Scientific Evidence
Medroxyprogesterone Acetate and Meningioma: A Global Issue
Roland N, Froelich S, Weill A (2025). Frontiers in Global Womens Health
View on PubMed→Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial Meningioma
Roland N, Neumann A, Hoisnard L, Gagne JJ, Froelich S, Weill A (2024). The BMJ
View on PubMed→The Association between Medroxyprogesterone Acetate Exposure and Meningioma
Griffin BR et al. (2024). Cancers
View on PubMed→Frequently Asked Questions
What is the Depo-Provera litigation about?
Do I qualify for a Depo-Provera lawsuit?
Is there a deadline to file a Depo-Provera claim?
How much does it cost to pursue a Depo-Provera claim?
What kinds of compensation can a Depo-Provera claim seek?
Related Pages
Depo-Provera Meningioma Brain Tumor
Meningioma — a tumor in the tissue surrounding the brain — is the primary injury in Depo-Provera lawsuits. Studies show long-term users face up to a 5.6x increased risk. The tumor can cause seizures, vision loss, and require major brain surgery.
Depo-Provera Brain Tumor Symptoms
Meningioma symptoms develop gradually and include persistent headaches, vision changes, seizures, and cognitive decline. If you used Depo-Provera and experience these symptoms, request brain imaging from your doctor.
Depo-Provera Long-Term Use Risks
Long-term Depo-Provera use carries multiple serious risks: meningioma brain tumors (up to 5.6x risk), significant bone density loss (black box warning), weight gain, depression, and delayed return to fertility. The FDA recommends limiting use to 2 years.
Depo-Provera Settlement Amounts
No Depo-Provera meningioma cases have settled or gone to trial yet. Projected settlements based on comparable pharmaceutical brain injury litigation suggest $75,000 to $1.5 million+ depending on injury severity.
Pfizer Depo-Provera Lawsuit
Pfizer inherited Depo-Provera when it acquired Pharmacia & Upjohn in 2002. Despite international warnings dating to 2015, Pfizer did not add a U.S. meningioma warning until December 2025. Plaintiffs allege a pattern of delayed safety action prioritizing revenue over patient safety.
Depo-Provera Alternatives After Diagnosis
If you are diagnosed with a meningioma, the FDA recommends discontinuing Depo-Provera immediately. Safer contraceptive alternatives exist that do not carry meningioma risk, including copper IUDs, barrier methods, and non-progestin options.
Depo-Provera MRI Screening
Current guidelines do not recommend routine MRI screening for asymptomatic Depo-Provera users. However, the updated FDA label instructs providers to monitor for meningioma symptoms. If you have symptoms, request brain imaging immediately.
Depo-Provera Brain Tumor Lawsuits Lawsuit
Depo-Provera (medroxyprogesterone acetate / MPA) is a contraceptive injection administered every three months. Over 2,000 lawsuits consolidated in MDL 3140 in the Northern District of Florida allege that Pfizer failed to warn about a significantly elevated risk of meningioma — a tumor in the tissue surrounding the brain and spinal cord. Women who received the shot for more than one year face up to a 5.6-fold increased risk, and the risk escalates with duration of use.
View full case overview